A multi-year framework brings locally manufactured insulin glargine to the essential-medicines list.
A multi-year framework agreement places locally manufactured insulin glargine on the national essential-medicines list, with reserved capacity for public tender.
The agreement covers supply of pre-filled pens and vials from the Calder Vale fill-finish campus, with release testing performed at the Ashcombe quality-control site under a single quality system.
Insulin is the clearest case for domestic manufacture. Demand is predictable, the cold chain is unforgiving, and an interruption is measured in hospital admissions rather than lost revenue.
Demand is predictable, the cold chain is unforgiving, and an interruption is measured in hospital admissions.
Under the framework, capacity is reserved rather than promised: a fixed share of each production campaign is allocated to the public tender before commercial orders are accepted.
First deliveries are scheduled for the second half of the year, following completion of process-validation batches.